Size: | Price | Quantity | |
---|---|---|---|
10 mg | $50.00 | ||
50 mg | $200.00 |
Obeticholic acid (459789-99-2) is a novel cholic acid analog which acts as a potent and selective FXR agonist (EC50= 99 nM). Displays anticholeretic activity in a rat model of cholestasis.1 Promotes adipocyte differentiation and regulates adipose cell function.2 Normalizes insulin sensitivity in a rabbit model of metabolic syndrome.3 A potentially new therapeutic agent for management of non-alcoholic fatty liver disease4 and NASH5. Displays therapeutic benefit in patients with primary biliary cirrhosis.6 Active in vivo.
References/Citations:
1) Fiorucci et al. (2005), Protective effects of 6-ethyl chenodeoxycholic acid, a farnesoid X receptor ligand, in estrogen-induced cholestasis; J. Pharmacol. Exp. Ther., 313 604
2) Rizzo et al. (2006), The farnesoid X receptor promotes adipocyte differentiation and regulates adipose cell function in vivo; Mol. Pharmacol., 70 1164
3) Maneschi et al. (2013), FXR activation normalizes insulin sensitivity in visceral preadipocytes of a rabbit model of MetS; J. Endocrinol., 218 215
4) Carr and Reid (2015), FXR agonists as therapeutic agents for non-alcoholic fatty liver disease; Curr. Atheroscler. Rep, 17 500
5) Jahn et al. (2016), Non-Alcoholic Steatohepatitis: From Pathophysiology to Novel Therapies; Dig. Dis., 34 356
6) Hirschfield et al. (2015), Efficacy of obeticholic acid in patients with primary biliary cirrhosis and inadequate response to ursodeoxycholic acid; Gastroenterology, 148 751
Materials provided by Focus Biomolecules are for laboratory research use only and are not intended for human or veterinary applications. Please note that we do not sell to individuals and that all orders placed by non-research organizations will incur a $20 restocking/refund fee
Obeticholic acid (459789-99-2) is a novel cholic acid analog which acts as a potent and selective FXR agonist (EC50= 99 nM). Displays anticholeretic activity in a rat model of cholestasis.1 Promotes adipocyte differentiation and regulates adipose cell function.2 Normalizes insulin sensitivity in a rabbit model of metabolic syndrome.3 A potentially new therapeutic agent for management of non-alcoholic fatty liver disease4 and NASH5. Displays therapeutic benefit in patients with primary biliary cirrhosis.6 Active in vivo.
References/Citations:
1) Fiorucci et al. (2005), Protective effects of 6-ethyl chenodeoxycholic acid, a farnesoid X receptor ligand, in estrogen-induced cholestasis; J. Pharmacol. Exp. Ther., 313 604
2) Rizzo et al. (2006), The farnesoid X receptor promotes adipocyte differentiation and regulates adipose cell function in vivo; Mol. Pharmacol., 70 1164
3) Maneschi et al. (2013), FXR activation normalizes insulin sensitivity in visceral preadipocytes of a rabbit model of MetS; J. Endocrinol., 218 215
4) Carr and Reid (2015), FXR agonists as therapeutic agents for non-alcoholic fatty liver disease; Curr. Atheroscler. Rep, 17 500
5) Jahn et al. (2016), Non-Alcoholic Steatohepatitis: From Pathophysiology to Novel Therapies; Dig. Dis., 34 356
6) Hirschfield et al. (2015), Efficacy of obeticholic acid in patients with primary biliary cirrhosis and inadequate response to ursodeoxycholic acid; Gastroenterology, 148 751
Calculate the molar concentration, mass or volume in a solution.
Concentration × Volume × Molecular Weight = Mass
For Postdoc
Customers!
Website Created by Advanta Advertising LLC.